dr aditya bardia discusses the advantages of sacituzumab govitecan for triple-negative breast cancer
Published 3 years ago • 295 plays • Length 2:23Download video MP4
Download video MP3
Similar videos
-
2:10
dr aditya bardia on how combining sacituzumab govitecan, talazoparib amplifies treatment response
-
2:44
dr aditya bardia forecasts what’s to come for the ascent trial in triple-negative breast cancer
-
2:40
dr. bardia on sacituzumab govitecan in triple-negative breast cancer
-
3:31
the ascent of sacituzumab govitecan in metastatic tnbc | aditya bardia
-
1:29
aditya bardia, md, mph, discusses the design of newly approved sacituzumab govitecan
-
7:42
the complexities of battling triple-negative breast cancer
-
5:46
understanding serds for hr breast cancer treatment: what you need to know
-
1:20:55
treatment of metastatic breast cancer
-
2:21
how immunotherapy might be effective for triple-negative breast cancer
-
0:57
dr. bardia on the role of the microenvironment in tnbc
-
0:59
dr. bardia on the results of the ascent trial in previously treated metastatic tnbc
-
9:30
exploring the treatment landscape for triple-negative breast cancer
-
10:06
triple negative breast cancer: what you need to know
-
12:38
triple-negative breast cancer: everything you need to know
-
1:55
an expert explains the three major treatment modalities in triple negative breast cancer
-
3:50
clinical approach to triple-negative breast cancer
-
1:12
dr. aditya bardia on rad1901 in er-positive metastatic breast cancer
-
1:33
dr. bardia describes the snapshot assay for breast cancer
-
2:41
dr. bardia on dual targeting of the her2 receptor
-
1:38
dr. bardia on the clinical utility of liquid biopsies in breast cancer
-
1:40
treatment of metastatic triple-negative breast cancer
-
26:31
targeting advanced triple-negative breast cancer | dana-farber cancer institute